Research & Innovation

The Epilepsy Foundation supports policies that promote research and innovation into new therapies and devices, as well as proposals to lift barriers to getting new treatments to patients faster. Innovation is of particular importance to the nearly one million people living with epilepsy who don’t have their seizures under control and are seeking new treatments and a cure, as well as many Americans living with complex chronic and rare conditions that are not appropriately managed with current treatment options. To help further research and innovation, we have supported the Advancing Research for Neurological Diseases Act (S. 849), which would create a system to gather data about neurological conditions and diseases.

 

Removing Barriers to Cannabis Research

The Epilepsy Foundation has actively advocated in support of several bills to reschedule cannabis and remove CBD from the Controlled Substances Act in the House and Senate, to remove federal barriers to research on the connection between cannabis and seizure control.

 

21st Century Cures

The Epilepsy Foundation supports the 21st Century Cures Act (H.R. 6), which would accelerate the discovery, development, and delivery of lifesaving medical treatments by bringing the nation’s health care innovation infrastructure into the 21st Century. We also support the Senate Innovation Package which combines a number of bills that are similar to provisions in the 21st Century Cures Act. 

 

Food and Drug Administration

The Epilepsy Foundation is engaged in PDUFA and MDUFA discussions with a focus on brining the patient voice into FDA’s review of drugs and devices.

 

Patents Reform 

A strong and secure patent system that encourages investments in innovative treatments and devices is critical for the millions of Americans waiting for breakthrough therapies and a cure to live their lives to their fullest potential.

 

Rare Epilepsies Network

The Rare Epilepsy Network, or REN for short, is a collaboration between the Epilepsy Foundation, RTI International, Columbia University and 23 different organizations that represent patients with a rare syndrome or disorder that is associated with epilepsy or seizures. The REN will establish a registry of patients, including patient or caregiver-reported data, to conduct patient-centered research.

 

Improving Access to New Therapies

The Epilepsy Foundation actively supported legislation signed by the President in November 2015 that will require the Drug Enforcement Administration (DEA) to schedule a new therapy within a set timeframe after approval by the Food and Drug Administration (FDA).

Reviewed on June 2016

Medicines in Development for Neurological Disorders

The Epilepsy Foundation has partnered with PhRMA on the release of a report on the drug development pipeline for neurological conditions. There are 420 medicines  (22 of them for epilepsy) in human clinical trials or under review by the Food and Drug Administration (FDA).

View the report and learn more at http://bit.ly/MedInDev.